'Unnecessarily complicated': Draft EU template on GMP standards for investigational drugs
This article was originally published in SRA
Parts of the new EU template for qualified persons to certify that investigational drugs from non-EU countries comply with good manufacturing practice standards are "unnecessarily complicated" and lack clarity, according to research-based EU pharma industry federation EFPIA1.
You may also be interested in...
New treatments for advanced endometrial cancer and hereditary angioedema are among six drugs that have just been recommended for EU-wide approval. Harmonized EU advice has also been issued in relation to an investigational antibody combination for treating COVID-19.
As part of its big data initiative, the European Medicines Agency is supporting projects that will help identify appropriate real-world data sources for regulatory decision making.
The European Medicines Agency may decide this week on a dozen requests by companies seeking new uses of their approved drugs.